This is the classic website, which will be retired eventually. Please visit the modernized ClinicalTrials.gov instead.
Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu
Trial record 1 of 1 for:    UC-HNG-2007
Previous Study | Return to List | Next Study

Study on the Efficacy of Treatment by Radiotherapy and Pembrolizumab in Newly Diagnosed Metastatic Head & Neck Cancers (PembroMetaRT)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT04747054
Recruitment Status : Recruiting
First Posted : February 10, 2021
Last Update Posted : October 13, 2023
Sponsor:
Collaborators:
GORTEC
National Cancer Institute, France
Information provided by (Responsible Party):
UNICANCER

Study Description
Go to 
Top of Page Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information
Brief Summary:
Study to evaluate the efficacy of treatment by radiotherapy and pembrolizumab in newly diagnosed metastatic head & neck cancers

Condition or disease Intervention/treatment Phase
Squamous Cell Carcinoma of Head and Neck Drug: Pembrolizumab Radiation: Loco-regional radiotherapy Drug: Chemotherapy Phase 3

Detailed Description:
Comparative interventional prospective phase 3, randomised, open-label, multicentric trial comparing the combination of radiotherapy and pembrolizumab alone or with chemotherapy to systemic treatment as first line treatment of patients with newly diagnosed head and neck squamous cell carcinoma with synchronous metastases.
Study Design
Go to 
Top of Page Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 148 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: Randomized Trial of Loco-regional Radiotherapy Added to Pembrolizumab Alone or With Chemotherapy Versus Systemic Treatment Alone for Patients With Newly Diagnosed Head and Neck Squamous Cell Carcinoma With Synchronous Metastases
Actual Study Start Date : December 1, 2021
Estimated Primary Completion Date : October 1, 2025
Estimated Study Completion Date : October 1, 2029

Resource links provided by the National Library of Medicine


Arms and Interventions
Go to 
Top of Page Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information

Arm Intervention/treatment
Experimental: Radiotherapy added to systemic treatment

Pembrolizumab 200 mg every 3 weeks until disease progression or unacceptable toxicity.

Loco-regional radiotherapy will start at D8 after the first administration of pembrolizumab (D1) with 54 Gy/18 fractions in the head and neck region.

If the investigator decides before randomization to add chemotherapy with pembrolizumab, the chemotherapy will start from cycle 3 or 4 of pembrolizumab (after radiotherapy administration) and will combine carboplatin AUC 5 mg/mL/min or cisplatin 100 mg/m² every 3 weeks with 5-FU 1000 mg/m²/day during 4 days every 3 weeks for a maximum of 6 cycles

 Drug: Pembrolizumab
Pembrolizumab 200 mg every 3 weeks until disease progression (as confirmed according to response evaluation criteria in solid tumors version 1.1 (RECIST v1.1)) or unacceptable toxicity. The treatment of pembrolizumab should not be delayed because of radiotherapy planning.
Other Name: KEYTRUDA

Radiation: Loco-regional radiotherapy
The loco-regional radiotherapy will start at D8 after the first administration of pembrolizumab (D1) (if delayed, RT should be started no later than three weeks after the first administration of pembrolizumab, i.e. before the second administration of pembrolizumab if possible), with 54 Gy/18 fractions in the head and neck region. The volume of RT will include only involved loco-regional tumor region and no prophylactic neck volume will be necessary.

Drug: Chemotherapy
If the investigator decides before randomization to add chemotherapy with pembrolizumab, the chemotherapy will be composed of carboplatin AUC 5 mg/mL/min or cisplatin 100 mg/m² every 3 weeks with 5-FU 1000 mg/m²/day during 4 days every 3 weeks for a maximum of 6 cycles
Active Comparator: Systemic treatment

Pembrolizumab 200 mg every 3 weeks until disease progression or unacceptable toxicity.

If the investigator decides before randomization to add chemotherapy with pembrolizumab, the chemotherapy will be composed of carboplatin AUC 5 mg/mL/min or cisplatin 100 mg/m² every 3 weeks with 5-FU 1000 mg/m²/day during 4 days every 3 weeks for a maximum of 6 cycles

 Drug: Pembrolizumab
Pembrolizumab 200 mg every 3 weeks until disease progression (as confirmed according to response evaluation criteria in solid tumors version 1.1 (RECIST v1.1)) or unacceptable toxicity. The treatment of pembrolizumab should not be delayed because of radiotherapy planning.
Other Name: KEYTRUDA

Drug: Chemotherapy
If the investigator decides before randomization to add chemotherapy with pembrolizumab, the chemotherapy will be composed of carboplatin AUC 5 mg/mL/min or cisplatin 100 mg/m² every 3 weeks with 5-FU 1000 mg/m²/day during 4 days every 3 weeks for a maximum of 6 cycles


Outcome Measures
Go to 
Top of Page Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information

Primary Outcome Measures :
  1. Progression-free survival (PFS) [ Time Frame: From randomization to disease progression or death, up to 3 years. ]
    The progression-free survival is the length of time during and after the treatment of a disease that a patient lives with the disease but it does not get worse.


Secondary Outcome Measures :
  1. Overall survival (OS) [ Time Frame: From randomization to death from any cause, up to 5 years. ]
    The overall survival is the length of time from randomization that patients enrolled in the study are still alive. The outcome is to evaluate whether the radiotherapy improves overall survival compared to standard of care.

  2. Quality of life questionnaire - Core 30 (QLQ-C30) [ Time Frame: At baseline, 4 months, 6 months, 12 months, 18 months, 2 years, 3 years, and 4 years ]
    Developed by the EORTC, this self-reported questionnaire assesses the health-related quality of life of cancer patients in clinical trials. The questionnaire includes five functional scales (physical, everyday activity, cognitive, emotional, and social), three symptom scales (fatigue, pain, nausea and vomiting), a health/quality of life overall scale, and a number of additional elements assessing common symptoms (including dyspnea, loss of appetite, insomnia, constipation, and diarrhea), as well as, the perceived financial impact of the disease. All of the scales and single-item measures range in score from 0 to 100. A high scale score represents a higher response level.

  3. Quality of Life Questionnaire - Head & Neck Cancer Module (QLQ-H&N35) [ Time Frame: At baseline, 4 months, 6 months, 12 months, 18 months, 2 years, 3 years, and 4 years ]
    The head & neck cancer module is a 35-item questionnaire designed for use among a wide range of patients with head & neck cancer, varying in disease stage and treatment modality. It includes 7 multi-item scales that assess pain (4 items), swallowing (4 items), senses (2 items), speech (3 items), social eating (4 items), social contact (5 items), and sexuality (2 items). There are also 11 single items. Using a 4-point Likert scale (1 = "not at all", 2 = "a little", 3 = "quite a bit", and 4 = "very much"), patients indicate the degree to which they have experienced symptoms. For all items and scales, high scores indicate more problems.

  4. Objective response rate (ORR) [ Time Frame: At 18 weeks and 21 weeks ]
    The Objective response rate is defined as the presence of a partial response (PR) or complete response (CR) observed at week 18. The investigator will evaluate the objective response using RECIST v1.1.

  5. Loco-regional progression [ Time Frame: From randomization to loco-regional progression, up to 5 years. ]
    Locoregional disease progression is defined as the time from randomization to the first documented locoregional progression evaluated by RECIST v1.1.

  6. Distant progression [ Time Frame: From randomization to distant progression, up to 5 years. ]
    Distant progression is defined as the time from randomization to the first documented distant disease progression evaluated by RECIST v1.1.

  7. Progression-free survival 2 (PFS2) [ Time Frame: Up to 5 years after randomization. ]
    Progression-free survival 2 is defined as time from randomization to a second tumor progression (according to RECIST V1.1) on next-line treatment (given after a first progression) or death from any cause. Patients who did not have a progression after the initial treatment are counted as an event at the time of death if they died whatever the cause of death or are censored at the time of last news if they are alive. Patients who had a progression after the initial treatment are counted as an event when they progressed again under or after the treatment of the first progression (if they start a new treatment, i.e. a third treatment, they are also counted as an event) or when they died whatever the cause of death or they are censored at the time of last news if they are alive without new progression after the first progression.

  8. Incidence of Treatment Adverse Events [ Time Frame: Throughout study completion, up to 5 years. ]
    The tolerance and safety will be evaluated by toxicity (acute [<1 months after the end of pembrolizumab] and late [≥1 month after the end of pembrolizumab]), assessed using the Common terminology criteria for adverse events version 5.0 (CTCAE v5.0).

  9. Compliance to treatment [ Time Frame: Throughout study treatment, up to 5 years ]
    Compliance to treatment is defined by the difference on recieved study regimen compared to the planned study regimen.


Eligibility Criteria
Go to 
Top of Page Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  1. Patient must have signed a written informed consent form prior to any study specific procedures. When the patient is physically unable to give their written consent, a trusted person of their choice, independent from the investigator or the sponsor, can confirm in writing the patient's consent.
  2. Newly diagnosed histologically confirmed squamous cell carcinoma of head and neck (oral cavity, oropharynx, hypopharynx, and larynx) with confirmed distant metastases at presentation (T1-4 N0-3 M1). Histological confirmation is required in case of a single metastatic lesion.
  3. Eligible for treatment by pembrolizumab according to the European Marketing Authorization
  4. Patient ≥18 years old
  5. Performance status: 0-1 (WHO)
  6. Combined Positive Score (CPS) ≥1 for primary tumor (as determined per local practice)
  7. Subjects must have at least one measurable lesion as per RECIST v1.1 to assess efficacy

  8. Adequate hematologic and end-organ function, defined by the following laboratory test results, obtained within 14 days prior to randomization:

    1. Absolute neutrophil count ≥1.5 × 10⁹/L
    2. Platelet ≥100 × 10⁹/L
    3. Hemoglobin ≥90 g/L
    4. Aspartate aminotransferase (AST) and alanine aminotransferase (ALT), ≤3 × upper limit of normal (ULN), (unless documented liver metastases where ≤5 x ULN is permitted)
    5. Bilirubin ≤1.5 × ULN.
    6. Serum albumin ≥25 g/L
    7. Creatinine clearance ≥30 mL/min (calculated per institutional guidelines or by Cockcroft-Gault or Modification of Diet in Renal Disease (MDRD) formula)
    8. Corrected serum calcium of ≤11.5 mg/dL or ≤2.6 mmol/L.
  9. Patient must agree to use adequate contraception methods for the duration of the study treatment and up to 4 months after the last dose of pembrolizumab administration
  10. Patients must be affiliated to a Social Security System (or equivalent)

Exclusion Criteria:

  1. Symptomatic central nervous system (CNS) metastases and / or carcinomatous meningitis
  2. History of another malignancy within 2 years prior to study inclusion, with the exception of completely resected basal or squamous cell skin cancer, or successfully treated in-situ carcinoma
  3. Prior radiotherapy in the head and neck region
  4. Any prior or current treatment for invasive head and neck cancer. This will include but is not limited to: prior tyrosine kinase inhibitors, any monoclonal antibody, chemotherapy, anti-PD-1/PD-L1 and CTLA-4, prior radiotherapy (RT), or use of any investigational agent
  5. Known Acquired Immune Deficiency Syndrome (AIDS)
  6. Known currently active infection including hepatitis B or hepatitis C
  7. Patient having received live attenuated vaccine within 28 days prior to enrolment
  8. Pregnant or breast feeding woman
  9. Active autoimmune disease except vitiligo, type-1 diabetes, hypothyroid stabilized with hormonal substitution, or psoriasis which do not require systemic treatment
  10. Active immunodeficiency or ongoing immunosuppressive therapy
  11. Active symptomatic interstitial lung disease
  12. Significant disease which, in the judgment of the investigator, as a result of the medical interview, physical examinations, or screening investigations would make the patient inappropriate for entry into the trial
  13. Any social, personal, medical, geographic and/or psychologic factor(s) that could interfere with the observance of the patient to the protocol and/or the follow-up and/or the signature of the informed consent
  14. Prior organ transplantation including allogenic stem-cell transplantation
  15. Other severe acute or chronic medical conditions including colitis, pneumonitis, pulmonary fibrosis or psychiatric conditions including active suicidal ideation; or laboratory abnormalities that may increase the risk associated with study participation and, in the judgment of the investigator, would make the patient inappropriate for entry into this study
  16. Person deprived of their liberty or under protective custody or guardianship
  17. Patient who have taken any investigational medicinal product or have used an investigational device within 30 days prior to study inclusion
Contacts and Locations
Go to 
Top of Page Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT04747054


Contacts
Layout table for location contacts
Contact: NICOLAS DE SOUSA CARVALHO 0171936709 n-de-sousa@unicancer.fr
Contact: LAURE MONARD 01 73 79 73 09 l-monard@unicancer.fr

Locations
Show Show 22 study locations
Sponsors and Collaborators
UNICANCER
GORTEC
National Cancer Institute, France
Investigators
Layout table for investigator information
Principal Investigator: Yungan TAO Gustave Roussy, Cancer Campus, Grand Paris
More Information
Go to 
Top of Page Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information
Layout table for additonal information
Responsible Party: UNICANCER
ClinicalTrials.gov Identifier: NCT04747054    
Other Study ID Numbers: UC-HNG-2007
2020-A02221-38 ( Other Identifier: ANSM )
First Posted: February 10, 2021    Key Record Dates
Last Update Posted: October 13, 2023
Last Verified: October 2023
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: No
Plan Description: Individual Participant Data will not be shared at an individual level. Those data will be part of the study database including all enrolled patients.

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: No
Studies a U.S. FDA-regulated Device Product: No
Keywords provided by UNICANCER:
Metastatic
Radiotherapy
pembrolizumab
 Squamous Cell Carcinoma
Head and Neck
Carcinoma
Additional relevant MeSH terms:
Layout table for MeSH terms
Carcinoma
Carcinoma, Squamous Cell
Squamous Cell Carcinoma of Head and Neck
Neoplasms, Glandular and Epithelial
Neoplasms by Histologic Type
Neoplasms
Neoplasms, Squamous Cell
 Head and Neck Neoplasms
Neoplasms by Site
Pembrolizumab
Antineoplastic Agents, Immunological
Antineoplastic Agents
Immune Checkpoint Inhibitors
Molecular Mechanisms of Pharmacological Action